Ionis Pharmaceuticals, Inc.
A biotech pioneer that designs medicines that target RNA—the body's genetic messengers—to treat diseases that were long considered "undruggable." Its medicines include SPINRAZA for spinal muscular atrophy and newer launches like WAINUA, TRYNGOLZA, and DAWNZERA, used mainly by patients with rare, neurological, and cardiometabolic conditions. Founded in 1989, it was originally named Isis Pharmaceuticals after the Egyptian goddess of healing, but renamed itself Ionis in 2015 to shake an unfortunate association with the militant group of the same name.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/APassive | 3.7% | 6.16M | May 15, 2026 |
| Capital World Investors | 13G/APassive | 12.8% | 21.19M | May 14, 2026 |
| Vanguard Capital Management | 13GPassive | 5.05% | 8.34M | Apr 30, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Wellington Management Group LLP | 13G/APassive | 4.3% | 6.88M | Aug 12, 2025 |
| Wellington Group Holdings LLP | 13G/APassive | 4.3% | 6.88M | Aug 12, 2025 |
| Wellington Investment Advisors Holdings LLP | 13G/APassive | 4.3% | 6.88M | Aug 12, 2025 |
| BlackRock, Inc. | 13G/APassive | 5.7% | 9.07M | Apr 17, 2025 |